医学
内窥镜检查
指南
普通外科
胃肠病学
内科学
病理
作者
Jorge D. Machicado,Sunil G. Sheth,Jean M. Chalhoub,Nauzer Forbes,Madhav Desai,Saowanee Ngamruengphong,Georgios I. Papachristou,Vaibhav Sahai,Ibrahim Nassour,Wasif M. Abidi,Omeed Alipour,Stuart K. Amateau,Nayantara Coelho–Prabhu,Natalie Cosgrove,Sherif Elhanafi,Larissa L. Fujii‐Lau,Divyanshoo R. Kohli,Neil B. Marya,Swati Pawa,Wenly Ruan,Nikhil R. Thiruvengadam,Nirav Thosani,Bashar J. Qumseya
标识
DOI:10.1016/j.gie.2024.06.002
摘要
This clinical practice guideline from the American Society for Gastrointestinal Endoscopy (ASGE) provides an evidence-based approach for the role of endoscopy in the diagnosis and management of pancreatic masses. This document was developed using the Grading of Recommendations Assessment, Development and Evaluation framework and addresses needle selection (fine-needle biopsy [FNB] needle vs FNA needle), needle caliber (22-gauge vs 25-gauge needles), FNB needle type (novel or contemporary [fork-tip and Franseen] vs alternative FNB needle designs), and sample processing (rapid on-site evaluation [ROSE] vs no ROSE). In addition, this guideline addresses stent selection (self-expandable metal stent [SEMS] vs plastic stent), SEMS type (covered [cSEMS] vs uncovered [uSEMS]), and pain management (celiac plexus neurolysis [CPN] vs medical analgesic therapy). In patients with solid pancreatic masses undergoing EUS-guided tissue acquisition (EUS-TA), the ASGE recommends FNB needles over FNA needles. With regard to needle caliber, the ASGE suggests 22-gauge over 25-gauge needles. When an FNB needle is used, the ASGE recommends using either a fork-tip or a Franseen needle over alternative FNB needle designs. After a sample has been obtained, the ASGE suggests against the routine use of ROSE in patients undergoing an initial EUS-TA of a solid pancreatic mass. In patients with distal malignant biliary obstruction undergoing drainage with ERCP, the ASGE suggests using SEMSs over plastic stents. In patients with proven malignancy undergoing SEMS placement, the ASGE suggests using cSEMSs over uSEMSs. If malignancy has not been histopathologically confirmed, the ASGE recommends against the use of uSEMSs. Finally, in patients with unresectable pancreatic cancer and abdominal pain, the ASGE suggests the use of CPN as an adjunct for the treatment of abdominal pain. This document outlines the process, analyses, and decision approaches used to reach the final recommendations and represents the official ASGE recommendations on the above topics.
科研通智能强力驱动
Strongly Powered by AbleSci AI